Everything below concerns 非天然氨基酸. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
The Racial Discrimination Act 1975 created the first general right against race discrimination. However, in 2019 the median adjusted weekly household income for Indigenous Australians over 15 was just $623 compared to $935 for non-Indigenous residents, a 33.3% race pay gap. In 2016, the census showed a gap of 72% employment for non-Indigenous Australians to just 47% employment rate for Indigenous Australians. There have not yet been institutions to set aside a portion of the funds from Australia's natural resources for Indigenous Australian well-being, nor are there yet clear principles established to ensure that historic disadvantage is undone, as in South Africa, India, or Europe, through positive action.
=== Guidelines === American Association of Blood Banks Clinical Practice Guidelines Australian National Blood Authority Patient Blood Management Guidelines British Committee for Standards in Haematology National Institute for Health and Care Excellence Blood Transfusion Guidance UK Guidance for transfusion. Canadian Blood Transfusion Guidelines German Medical Association Guidelines (English) Archived 2022-04-01 at the Wayback Machine, published 2014.
Charcot–Marie–Tooth disease was first discovered in 1886 by three scientists: Jean-Martin Charcot (1825–1893) and his assistant Pierre Marie (1853–1940), along with the English doctor Howard Henry Tooth (1856–1925). In their original publication, titled “Concerning a Special Form of Progressive Muscular Atrophy,” Charcot and Marie acknowledged that similar cases had been previously published in medical literature. Their findings described hereditary neuropathy, marked by gradual muscle wasting and diminished sensation in the extremities. This crucial discovery helped establish CMT as a distinct clinical entity, differentiating it from other neuromuscular conditions such as muscular dystrophies. Over the years, advancements in neurogenetics have led to the identification of various genetic mutations responsible for the disease, significantly enhancing our understanding of its pathogenesis and classification. Charcot also noted that prior descriptions of the disease were neither objective nor thorough. Most of the earlier accounts merely mentioned that CMT was hereditary. As a result, Charcot felt it was essential to provide a comprehensive description of the disease, ensuring that it received the attention it deserved. In 2010, Charcot–Marie–Tooth (CMT) disease became one of the first conditions in which the precise genetic cause was identified in an individual patient using whole-genome sequencing. This groundbreaking discovery was made by scientists affiliated with the Charcot–Marie–Tooth Association (CMTA).
An FC soldier was slightly injured in a drone attack on a post in Bannu District. A soldier from Sindh Regiment was killed in an engagement with militants near the border in Orakzai District. Five personnel from a Bomb Disposal Unit were killed in a militant attack in North Waziristan. A soldier was injured in an IED explosion in Karak District. Eight TTP militants were killed in a military IBO in Dosali. On 22 June, an insurgent commander was killed at South Waziristan-Chaman border. On 23 June, a civilian was injured in a militant drone strike on a rickshaw in Bannu District, while an FC soldier and a sweeper at a police station were abducted, the Bannu cantonment was hit twice with mortar shells. A government school in South Waziristan was destroyed by militants. Several artillery and mortar shells fired from Afghanistan hit Angoor Adda and Zalol Khel, two unexploded shells were also recovered from Bajaur District. On 24 June, a school in South Waziristan was destroyed by insurgents. Eight policemen including an SHO were abducted from South Waziristan. CTD killed six TTP militants in an operation in Lower Dir. Four TTP militants were killed in an operation near Miramshah and four more in Tank District whereas a TTP attack in Hangu District was repulsed, a soldier also died in the operation in Tank District. A quadcopter strike on a police station in Bannu District wounded two policemen whereas a school headmaster was also abducted from the district. An airstrike in South Waziristan killed two TTP insurgents.
Cytochromes c (cyt c, c-type cytochromes) cytochromes, or heme-containing proteins, that have heme C covalently attached to the peptide backbone via one or two thioether bonds. These bonds are in most cases part of a specific Cys-X-X-Cys-His (CXXCH) binding motif, where X denotes a miscellaneous amino acid. Two thioether bonds of cysteine residues bind to the vinyl sidechains of heme, and the histidine residue coordinates one axial binding site of the heme iron. Less common binding motifs can include a single thioether linkage, a lysine or a methionine instead of the axial histidine or a CXnCH binding motif with n>2. The second axial site of the iron can be coordinated by amino acids of the protein, substrate molecules or water. Cytochromes c possess a wide range of properties and function as electron transfer proteins or catalyse chemical reactions involving redox processes. A prominent member of this family is mitochondrial cytochrome c.
Sources: en.wikipedia.org
== Clinical significance == Variants of PCSK9 can reduce or increase circulating cholesterol. LDL-particles are removed from the blood when they bind to LDLR on the surface of cells, including liver cells, and are taken inside the cells. When PCSK9 binds to an LDLR, the receptor is destroyed along with the LDL particle. PCSK9 degrades LDLR by preventing the hairpin conformational change of LDLR. If PCSK9 does not bind, the receptor will return to the surface of the cell and can continue to remove LDL-particles from the bloodstream. Other variants are associated with a rare autosomal dominant familial hypercholesterolemia (HCHOLA3). The mutations increase its protease activity, reducing LDLR levels and preventing the uptake of cholesterol into the cells. In humans, PCSK9 was initially discovered as a protein expressed in the brain. However, it has also been described in the kidney, the pancreas, liver and small intestine. Recent evidence indicate that PCSK9 is highly expressed in arterial walls such as endothelium, smooth muscle cells, and macrophages, with a local effect that can regulate vascular homeostasis and atherosclerosis. Accordingly, it is now very clear that PCSK9 has pro-atherosclerotic effects and regulates lipoprotein synthesis. As PCSK9 binds to LDLR, which prevents the removal of LDL-particles from the blood plasma, several studies have determined the potential use of PCSK9 inhibitors in the treatment of hyperlipoproteinemia (commonly called hypercholesterolemia).
The Gjyshata of Gjirokastra (headquarters: tekke of Asim Bab): the regions of Gjirokastra, Saranda and Tepelena. The Gjyshata of Korça (headquarters: tekke of Turan): the regions of Korça, Devoll, Pogradec and Kolonja, including Leskovik. The Gjyshata of Kruja (headquarters: tekke of Fushë Kruj): the regions of Kruja, Kurbin, Bulqiza, Dibra, Mat, Shkodra and Durrës. The Gjyshata of Elbasan (headquarters: tekke of Baba Xhefai): the regions of Elbasan, Gramsh, Peqin, Lushnja, Kavaja, and Librazhd, including Përrenjas. The Gjyshata of Vlora (headquarters: tekke of Kusum Bab): the regions of Vlora, Mallakastra, Fier, including Patos and Roskovec. The Gjyshata of Berat (headquarters: tekke of Prisht): the regions of Berat, Skrapar and Përmet. During the 1930s, the six gjyshata of Albania set up by Sali Njazi were:
=== Box office === Nutty Professor II: The Klumps grossed $42.5 million in its opening weekend, beating out What Lies Beneath and Thomas and the Magic Railroad to reach the number one spot. At the time, it had the third-highest opening weekend for a 2000 film, behind Mission: Impossible 2 and X-Men. This also made it the biggest opening weekend for an Imagine Entertainment film, beating Ransom. The film would hold this record four months until How the Grinch Stole Christmas replaced it that November. It set a career record for Eddie Murphy, breaking the three-day record formerly held by Dr. Dolittle. The film managed to secure the fourth-highest July opening weekend, after X-Men, Men in Black and Independence Day. For its second weekend, it fell into second place behind Hollow Man with $18 million. In the United Kingdom, Nutty Professor II: The Klumps made $2.3 million in its opening weekend, ranking number one ahead of Hollow Man and Billy Elliot. It dropped into fourth place behind Dinosaur, Road Trip and Billy Elliot during its second weekend with $1.3 million. The film went on to generate a total gross of over $123.3 million in the United States and an additional $43 million in other territories, for a worldwide total of $166.3 million worldwide.
The ionic concentrations of hydrothermal vents differs from the intracellular fluid within the majority of life. It has instead been suggested that terrestrial freshwater environments are more likely to be an ideal environment for the formation of early cells. Meanwhile, proponents of the deep sea hydrothermal vent hypothesis suggest thermophoresis in mineral cavities to be an alternative compartment for polymerization of biopolymers. How thermophoresis within mineral cavities could promote coding and metabolism is unknown. Nick Lane suggests that nucleotide polymerization at high concentrations of nucleotides within self-replicating protocells, where "Molecular crowding and phosphorylation in such confined, high-energy protocells could potentially promote the polymerization of nucleotides to form RNA". Acetyl phosphate could possibly promote polymerization at mineral surfaces or at low water activity. A computational simulation shows that nucleotide concentration of nucleotide catalysis of "the energy currency pathway is favored, as energy is limiting; favoring this pathway feeds forward into a greater nucleotide synthesis". Fast nucleotide catalysis of CO2 fixation lowers nucleotide concentration as protocell growth and division is rapid which then leads to halving of nucleotide concentration, weak nucleotide catalysis of CO2 fixation promotes little to protocell growth and division.
== Function == The adiponectin receptors, AdipoR1 and AdipoR2, serve as receptors for globular and full-length adiponectin and mediate increased AMPK and PPAR-α ligand activities, as well as fatty acid oxidation and glucose uptake by adiponectin. In 2016, the University of Tokyo announced that it would launch an investigation into claims of fabrication of AdipoR1 and AdipoR2 identification data, as accused by an anonymous person/group called Ordinary researchers.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.